FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFI	CIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MacLean Michael F				2. Issuer Name and Ticker or Trading Symbol Verve Therapeutics, Inc. [VERV]							(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
WideLean Wilchael F							-	-						X Directo	or		10% Ow	ner	
(Last)	•	irst) APEUTICS, INC	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/17/2021									Officer below)	(give title		Other (s below)	pecify	
500 TEC	HNOLOG	Y SQUARE, SU	ITE 901		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	IDGE M	IA	02139										X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date					action 2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr. 5)				Benefici	es Form ally (D) of following (I) (II		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code V	Am	nount	(A) or (D)		Transaci (Instr. 3	tion(s)			msu. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)		ate, Ti	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		and	7. Title and of Securiti Underlying Derivative (Instr. 3 and	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				С	ode	v	(A)	(D)	Date Exercisable	Expira Date	ation	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$19	06/17/2021			A		47,664		(1)	06/16/	/2031	Common Stock	47,664	\$0.00	47,664	4	D		

1. The option was granted on June 17, 2021. The shares underlying the option vest quarterly over four years in 16 equal installments following May 20, 2021.

Remarks:

/s/ Andrew Ashe, Attorney-in-Fact For Michael MacLean

06/21/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).